Background: Only a few reports on the clinical features and management of childhood leiomyosarcoma are available. To contribute additional information on the management of this rare tumor, we report on a series of 16 pediatric patients treated from 1982 to 1998 by the Soft Tissue Sarcoma Italian Cooperative Group.
Introduction
Malignant smooth muscle tumors are uncommon neoplasms and are particularly rare in childhood, accounting for 2%-4% of soft tissue sarcomas [1] . Only a few reports are available on the clinical features and management of childhood leiomyosarcoma [2] [3] [4] [5] [6] [7] . Unlike the adult form, pediatric leiomyosarcoma arises less commonly in the retroperitoneum and genitourinary tract, the most frequent primary site being the gastrointestinal tract (especially the stomach), and head and neck soft tissue [8, 9] .
Complete surgical resection is the treatment of choice [1] . The prognosis is usually good for neoplasms arising outside the gastrointestinal tract and when the tumor can be completely excised [10] . The role of adjuvant chemotherapy and radiation therapy is not defined as yet [l] .
In order to contribute further information to the management of this rare tumor, we report on a series of pediatric patients with leiomyosarcoma treated by the Soft Tissue Sarcoma Italian Cooperative Group (STS-ICG), affiliated to the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica).
Patients and methods
Between January 1982 and December 1998. 16 consecutive children with leiomyosarcoma were treated by Centers taking part in the AIEOP. The clinical data, histopathologic findings and treatment modalities were reviewed for each patient. There were eight males and nine females, and the median age at diagnosis was 12 years (range 2-21 years). The time elapsing between the onset of symptoms and diagnosis ranged from 1 to 18 months (median five months). In most cases the sign leading to diagnosis was a soft tissue mass, with or without pain. The site of the primary tumor was the head and neck in five cases, the gastrointestinal tract in four (one stomach, one small intestine, two large intestine), the lower extremities in two. the pelvis in two. and the trunk, the lung, and the liver in one case each In two patients, leiomyosarcoma was diagnosed as a second tumor: a 21-year-old boy developed a pelvic leiomyosarcoma 10 years after Hodgkin's disease and treatment with six cycles of MOPP (mechlorethamine, vincnsline, procarbazine. prednisone). chemotherapy and radiotherapy (leiomyosarcoma arose outside radiation fields); another patient had a leiomyosarcoma of the zygomatic soft tissues (with bone and lung metastases) seven years after ipsilateral retinoblasloma treated with radiotherapy.
Representative slides or blocks were available for central pathology review in 12 cases. The diagnosis was based on the same histologic and immunohistochemical criteria as the adult counterpart' elongated or fusiform cells, arranged in interweaving fascicles with eosinophilic cytoplasm, cigar-shaped nuclei, and frequent PAS positive paranuclear citoplasmic vacuoles considered indicative for smooth muscle differentiation. A confirmation was given by immunohistochemistry with a cytoplasmic posilivity, even focal, for desmin or alpha smooth muscle aclin, combined with negativity for markers of skeletal muscle differentiation (MyoDl. Myf3. and Myf4). The presence of isolated SIOO or citokeralin positive cells was not considered against the diagnosis of leiomyosarcoma. A grading was assigned according to the French grading system [II], based on a score generated by evaluating three parameters tumor differentiation, mitotic rate and amount of tumor necrosis. Among the reviewed cases, nine were Gl. one was G2. and two were G3.
The tumor extent was assessed according to the Tumor-NodesMetastases (TNM) pretreatment staging system, and the Intergroup Rhabdomyosarcoma Study (IRS) post-surgical grouping system. The TNM Tl refers to tumors confined to the organ or tissue of origin, while T2 lesions invade contiguous structures, Tl and T2 groups are further divided into A or B according to tumor diameter < or >5 cm, respectively [12] . After initial surgery, the patients were classified according to the IRS system-group 1 defines completely excised tumors, group II grossly resected tumors with microscopic residual disease, group III includes patients with gross residual disease after incomplete resection or biopsy, group IV patients with metastases at onset [13] .
Patients were treated using multimodality therapeutic approaches including surgery, chemotherapy, and radiotherapy, based on the ongoing protocols. The general therapeutic approach did not change during the years of the study and was planned taking into consideration the primary tumor size and site, local invasiveness. regional and distant spread, histologic grading, and the age of patient. When feasible, conservative surgery was the primary treatment. With the exception of two patients, primary excision was attempted when complete and non-mutilating resection was considered possible, otherwise a biopsy was performed Re-surgery (primary re-excision) was recommended prior to any other treatment in the event of suspicious microscopic residual disease, to ensure radical resection with free margins. When the disease was considered unresectable at diagnosis, surgery was postponed until after the administration of chemotherapy to shrink the tumor and make it more resectable.
The therapeutic guidelines were to use surgery alone if complete resection could be achieved. Chemotherapy and/or radiotherapy were recommended if micro-or macroscopical residual disease were present after surgery, different protocols being adopted over the years.
Chemotherapy was administered to 9 out of 16 patients, four patients were treated with VACA regimen, two with IVA, one with VAIA (see Table I ), the two metastatic patients were treated with CEVAIE regimen, followed in one case by high-dose melphalan with aulologous bone marrow transplantation, according to the European Intergroup Study MMT4-9I [14] .
Event-free survival (EFS) and overall survival (OS) were estimated according to the Kaplan-Meier method [15] . Patients were evaluated from the date of diagnosis to disease progression, relapse, or death from any cause (whichever occurred first) for EFS. and to death for OS. The time scale extended up to the latest follow-up if no event was observed. The log-rank test was used to compare the survival curves of the different subgroups of patients, in order to define the potential value of prognostic factors [16] . Patient follow-up up to October 2000, ranged from 3 to 18 years (median seven years).
Tumor response was evaluated in all protocols after 9-10 weeks of initial chemotherapy. Response to treatment, based on the degree of the decrease in the sum of the products of the perpendicular diameters of all measurable lesions, was defined as follows: complete response (CR) = the complete disappearance of disease; partial response (PR) = a tumor reduction > 50%; minor response (MR) = a reduction > 25% Stable disease or a reduction <25% was recorded as no response, while an increase in tumor size or the detection of new lesions was considered as progression of disease
Results
According to the TNM system, six children were classified as T1A, three as TIB, two as T2A, and five as T2B.
At diagnosis, two patients presented with nodal involvement, and two had distant metastases (one patient with leiomyosarcoma of the small intestine had a single liver metastasis, one with head and neck tumor had bone and lung metastases). Maximum tumor diameter ranged from 2 to 15 cm (median 4 cm), and was ^ 5 cm in 8 cases and > 5 cm in 8.
The primary surgical approach was conservative in all but two patients, operated before admission to an AIEOP center, i.e. a boy with a large T2B tumor of the left foot, which was amputated, and a girl submitted to gastrectomy. The post-surgical IRS staging was: eight group I, three group II, three group III, and two group IV.
Nine patients underwent radical tumor resection as primary treatment: eigth had localized disease and were classified as IRS group I; the other patient had metastatic disease and underwent radical resection both of the primary tumor (located in the small intestine) and of the solitary liver metastasis. In four cases, tumor excision with histopathologically free margins (surgical radicality) was achieved through a primary re-excision performed within two months of the first approach. Four patients had non-radical surgery, which consisted of marginal resection with microscopic residual disease in three (IRS group II), and intralesional resection with gross residual tumor in one (group III). In three patients primary surgery consisted of biopsy (two IRS group III patients and one metastatic patient). Primary surgery included regional lymphadenectomy in the two patients with nodal involvement.
In two IRS group III patients, radical resection was achieved by secondary conservative surgery following chemotherapy, which induced tumor partial remission in only one case.
Chemotherapy was administered to 9 out of 16 patients: 2 of 8 IRS group I patients, 2 of 3 group II, 3 of 3 group III, and 2 of 2 group IV. Two group I patients did receive chemotherapy, one because the physician concerned chose not to follow the protocol, the other because a huge tumor infiltrating contiguous structures, with a G3 histologic grade was located in a lower limb, which was amputated. In one case with microscopical residual tumor, chemotherapy was refused by parents. Among the nine patients who received chemotherapy, response was evaluable in four cases with measurable disease (three group III, one group IV): a partial response (to the VACA regimen) in one group III case, and no response in three.
Radiation therapy was delivered to three patients. A 21-year-old patient with a T2B pelvic tumor who underwent non-radical surgery was treated with external beam irradiation at a dose of 40 Gy. An 11-year-old boy with a leiomyosarcoma of the calf was treated with external radiotherapy at a dose of 40 Gy and with brachytherapy at a dose of 15 Gy, with complete resection after chemotherapy. A 15-year-old girl was treated with external radiation with 44.8 Gy after non-radical surgery of a stomach leiomyosarcoma with node involve- Abbreviations: S -surgery; RT -radiotherapy, CT -chemotherapy; IRS -Intergroup Rhabdomyosarcoma Study. TNM -tumor-nodesmetastases; VACA -vincristine 1.5 mg/sqm/week, weeks 1-4, adnamycin 30 mg/sqm x 2, weeks 1 and 7, cyclophosphamide 1200 mg/sqm. weeks I, 4 and 7, actinomycin-D 0.5 mg/sqm/day x 3, week 4, IVA -ifosfamide 3 g/sqm/day x 2. vincristine 1.5 mg/sqm (max 2 mg), actinomycin-D 1.5 mg/sqm (max 2 mg), CEVAIE -carboplatin 500 mg/sqm, week 1, epiadriamycin 150 mg/sqm. week 1. ifosfamide 3 g/sqm/day x 3. weeks 4 and 7, actinomycin-D 1.5 mg/sqm/day (max 2 mg), week 4, etoposide 200 mg/sqm/day x 3, week 7, vincristine 1.5 mg/sqm (max 2 mg). weeks 1,2,3,4,5,7 and 8; ABMT -autologous bone marrow transplantation; VAIA -ifosfamide 3 g/sqm/day x 2. weeks 1,4 and 7, actinomycin-D 0.5 mg/sqm/day (max 0.5 mg) x 3, weeks I and 7, vincnstine 1.5 mg/sqm (max 2 mg), weeks 1, 2, 3, 4 and 7, adriamycin 40 mg/sqm/day x 2. week 4; CR -complete remission, DOD -dead of disease, SD -stable disease, PR -partial remission° In patients nos. 7 and 13, leiomyosarcoma occurred as a second tumor b Brachitherapy ment. A subset of patients with residual disease after primary surgery was not treated with irradiation. In one group II patient radiotherapy was refused by parents. In two group III patients radiotherapy was not delivered as first line treatment due to the rapid progression of the disease in one case, and due to the complete resection of the tumor in second surgery following chemotherapy in the other. No data were available to assess any response to radiotherapy, due to the absence of measurable disease in those patients.
The treatment was devoid of severe acute toxicity, acute reactions consisting primarily of alopecia and vomiting, without the occurrence of life-threatening myelosuppression or fatal toxic event. To date none of the patients have developed late iatrogenic effects.
After a median follow-up of seven years (range 3-18), the five-year EFS and OS were 56.3% (SE 12.4%) and 72.9% (SE 11.7%), respectively.
At the cut-off date of analysis, 12 out of 16 patients were alive, nine in first CR. Two children were in second CR 30 and 60 months after a local relapse and a peritoneal relapse (from a leiomyosarcoma of small intestine) treated with either surgery or chemotherapy. One patient was alive with progressive disease after metastatic relapse (in lung and liver).
Of the seven patients whose treatment failed, at 2-48 months (median 12 months) from diagnosis, recurrence was local in two cases, local with pulmonary metastases in one, distant in four (one lung, one lung and bone, one lung and liver, one peritoneum). Among the relapsing patients, four had Gl histologic grading and two had G3 (one grading not available); three were staged as T2B, three as TIB and one asTIA; 6 of 7 had leiomyosarcoma > 5 cm; according to the IRS grouping, two belonged to group I, two to group II, one to group III, and two to group IV. Four of the seven relapsing patients died of their disease at 6-48 months (median 30 months) from diagnosis.
The outcome was evaluated in relation to the extent of primary surgery, tumor size, local invasiveness, and age, and survival curves were compared in univariate analysis.
Size seemed to represent a statistically significant factor, in spite of the small number of patient included in the analysis: five-year EFS was 87.5% and 25%, in the cohort of patients with tumor smaller and larger than 5 cm, respectively (/> = 0.0090), while five-year S was 100% and 45% (P = not calculable). Considering local invasiveness, five-year EFS was 55.6% in Tl and 57.1% in T2 patients (P = 0.7531). Comparing IRS group I (microscopical complete resection) vs. group II-III-IV, five-year EFS was 75% and 37.5%, respectively (P = 0.1330). Finally, according to age, five-year EFS in children younger and older than 10 years was 66.7% and 50% {P = 0.3554), respectively.
If we compare patients submitted or not submitted to chemotherapy, five-year EFS was respectively 44.4% and 71.4% (P = 0.3093).
Discussion
The rarity of leiomyosarcoma in pediatric age accounts for the scant published reports and the few data available on its clinical features and management [2] [3] [4] [5] [6] [7] . In all reports, childhood leiomyosarcoma seems to behave better than in adults, in whom the retroperitoneal and genitourinary sites are predominant [17] [18] [19] .
The most significant series on leiomyosarcoma in children and adolescents remains the one reported by the Memorial Sloan-Kettering Cancer Center (MSKCC), with a single-institution cohort of 21 pediatric patients treated between 1952 and 1994 [6] . In this series, 10 patients had primary radical surgery, and 11 underwent non-radical resection; radiation therapy was given to nine patients, and chemotherapy (usually adriamycin and cisplatin) to 13. Their results showed that complete resection was the treatment of choice and represented the most important predictor of outcome. Similar conclusions can be drawn from our report, where the small number of patients limited the significance of a statistical analysis and the value of the prognostic factors: IRS group I patients had a five-year EFS of 75% (vs. 37.5% for group II-III-IV), while of the 11 cases who underwent radical resection (at diagnosis or at delayed surgery after chemotherapy) eight were in first CR and two in second CR.
The five-year OS in the MSKCC's patients was 79%, but a progressive decrease was evident with time, with a 10-year OS of 49%. In fact three patients died of their disease more than 10 years after diagnosis [6] . This finding suggests that a long follow-up period is mandatory, and this must be taken into account when considering EFS and OS in our series, even if the median follow-up of our cohort was seven years and the median time of relapse was 12 months.
In our series, the small number of patients might interfere with the evaluation of well-known prognostic factors assessed in larger adult series [17, [20] [21] [22] , such as tumor site and particularly histopathological grading. For the MSKCC's cohort, however, though comparable with ours in terms of the number of patients, the authors suggested a strong correlation between tumor grade and resectability [6] . In the clinico-pathological report on 10 pediatric cases from Lack et al., mitotic rates represented the most important histologic predictor of malignancy [4] . Similar to the recently published series of De Saint Aubain Somerhausen et al. [7] , in our cohort the histologic grade was low in the majority of cases: the only two patients with G3 leiomyosarcoma experienced metastatic recurrence. De Saint Aubain Somerhausen et al. [7] , reported on 20 children younger than 16 years with non-visceral soft tissue leiomyosarcoma, with particular remarks on histopathologic findings. In that series there were only two local recurrences and no metastatic relapse or death in 15 patients with follow-up information. The good prognosis might be influenced by the histologic grade, but it was probably also related to the absence of gastrointestinal and vis-ceral tumors, and the high rate of small size and superficial location.
In our experience, the prognostic role of age at diagnosis seemed uncertain: no patient younger than 10 years died of disease, but there was no statistically significant difference between the outcome of patients younger or older than 10 years. We found no significant correlation between age and tumor size, invasiveness, site, or type of initial surgery. It may be that leiomyosarcoma has less aggressive behaviour in younger children, rather like the situation described for pediatric fibrosarcomas. In adult series [20, 22] , older age is a predictor of worse prognosis, due to the greater incidence of high-grade tumors.
In agreement with other authors [17] , in our series tumor size represented the most important and the only statistically significant risk factor. It is worth noting that all but one relapsing patients had tumors > 5 cm, and no patient with tumor ^ 5 cm died of disease, the fiveyear EFS was 87.5% for patients with tumor ^ 5 cm and 25% for those with tumors > 5 cm, P = 0.0090. Tumor size appeared to be correlated with invasiveness of contiguous structures and the feasibility of radical resection: six patients with T1A tumor were classified as IRS group I, and all were alive, 5 of 6 in first CR.
As in other soft tissue sarcomas of childhood or adult age, in the treatment of leiomyosarcoma the actual effectiveness of radiotherapy and chemotherapy remains to be established. Some reports suggested that radiotherapy could improve local control of tumors that cannot be completely resected, particularly in the case of microscopic residual tumor after surgery [23] [24] [25] . In our series radiotherapy was used in addition to surgery in only three cases. Two of the three patients with microscopic residual disease were irradiated and showed disease-free survival.
Chemotherapy, especially adriamycin-based regimens, is thought to have a possible role in the adjuvant treatment of leiomyosarcomas in adults [26] [27] [28] , while in children there is only limited experience [6] . In our series, we observed only one partial response to a multidrug regimen among the 4 evaluable cases. There was no clear evidence that the use of chemotherapy enabled surgical resection considered unfeasible at diagnosis, or that it contributed to the achievement of a favorable overall outcome in our cohort. No real differences in outcome were observed in patients submitted or not submitted to chemotherapy.
In two of our patients, leiomyosarcoma developed as a second tumor: after Hodgkin's disease (outside the radiation field) in one case; after retinoblastoma (at the radiation field margin) in the other. The etiological relationship between immunosuppression and smooth muscle tumors is well known [1] . Leiomyosarcomas have been reported in patients with acquired immuno deficiency syndrome (recently also linked to Epstein-Barr virus [29] ), after treatment for acute lymphocytic leukemia or Hodgkin's disease [30] , after radiation therapy [31] , and during immunosuppressive treatment in organ transplant recipients [1] . In addition, the association with retinoblastoma has been reported, both inside and outside the radiation fields, suggesting a role of RBI gene mutation [32] .
In conclusion, our report attempts to contribute to guiding the clinical management of this rare tumor. In our experience, complete surgical resection, with ample excision to ensure histopathologically tumor-free margins, represents the mainstay of treatment [23] . Complete surgery can also be obtained by a primary re-excision following inadequate primary operation, as was the case in four of our patients.
In relation to the unclear role of adjuvant therapy, in the case of small leiomyosarcomas (less than 5 cm), limited to the original structures (T1A), complete surgery (IRS group I) may represent the only treatment. All such cases in our series -five patients -were still alive, four in continuous CR and one in second CR.
We were unable to confirm a clear benefit of radiotherapy, though it may have contributed to controlling disease in two patients with microscopic residual disease after surgery. There was also no clear evidence that the use of chemotherapy enabled a previously unfeasible surgical resection, or that it contributed to the favorable overall outcome in our series. In our opinion, postsurgical treatment should be implemented only in patients with unfavorable features, e.g. large invasive tumor difficult to resect at diagnosis. The role of age should be investigated in pediatric patients.
While complete surgical resection remains the best primary treatment for leiomyosarcoma, multicentric cooperative prospective studies are needed to evaluate the role of chemotherapy and radiotherapy. A suggestive proposal to define a consensus statement and unify treatment management could be a collaborative minimeta-analysis involving all reported series.
